Eli Lilly’s Zepbound Poised to Outpace Novo Nordisk’s Wegovy in the Obesity Treatment Market
Clinical trials show Eli Lilly’s Zepbound achieves greater weight loss than Wegovy, making it a strong contender in the obesity treatment market. Its potential cost-effectiveness further positions Zepbound as a leading treatment option.